Iterum Therapeutics Plc Stock Investor Sentiment
| ITRM Stock | USD 1.55 0.03 1.90% |
About 55% of Iterum Therapeutics' investors are presently thinking to get in. The analysis of overall sentiment of trading Iterum Therapeutics PLC stock suggests that some investors are interested at this time. Iterum Therapeutics' investor sentiment overview provides quick insight into current market opportunities from investing in Iterum Therapeutics PLC. The current market sentiment, together with Iterum Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Iterum Therapeutics PLC stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Iterum Therapeutics stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Iterum daily returns and investor perception about the current price of Iterum Therapeutics PLC as well as its diversification or hedging effects on your existing portfolios.
Iterum |
Iterum Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Iterum Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about Iterum Therapeutics that are available to investors today. That information is available publicly through Iterum media outlets and privately through word of mouth or via Iterum internal channels. However, regardless of the origin, that massive amount of Iterum data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Iterum Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Iterum Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Iterum Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Iterum Therapeutics alpha.
Iterum Therapeutics Performance against NYSE Composite
Price Growth (%) |
| Timeline |
1 | Purchase by Kelly David George of 10000 shares of Iterum Therapeutics | 02/26/2024 |
2 | Iterum stock spikes on plans for FDA filing | 03/06/2024 |
3 | Iterum Therapeutics PLC Up 5.81 percent in Premarket Trading - InvestorsObserver | 03/11/2024 |
4 | Iterum Therapeutics to Participate in H.C. Wainwright Virtual Home Fireside Chat | 03/15/2024 |
5 | Iterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024 | 03/21/2024 |
6 | Iterum Therapeutics PLC expected to post a loss of 93 cents a share - Earnings Preview - XM | 03/26/2024 |
7 | ITRM Stock Earnings Iterum Therapeutics Beats EPS for Q4 2023 | 03/28/2024 |
8 | Iterum Therapeutics plc Q4 2023 Earnings Call Transcript | 04/02/2024 |
9 | Insider Trading | 04/18/2024 |
10 | Acquisition by Sailaja Puttagunta of 1800000 shares of Iterum Therapeutics at 0.48 subject to Rule 16b-3 | 04/22/2024 |
Check out Iterum Therapeutics Hype Analysis, Iterum Therapeutics Correlation and Iterum Therapeutics Performance. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Complementary Tools for Iterum Stock analysis
When running Iterum Therapeutics' price analysis, check to measure Iterum Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iterum Therapeutics is operating at the current time. Most of Iterum Therapeutics' value examination focuses on studying past and present price action to predict the probability of Iterum Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iterum Therapeutics' price. Additionally, you may evaluate how the addition of Iterum Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |
Is Iterum Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iterum Therapeutics. If investors know Iterum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iterum Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.96) | Quarterly Revenue Growth (1.00) | Return On Assets (0.64) | Return On Equity (3.55) |
The market value of Iterum Therapeutics PLC is measured differently than its book value, which is the value of Iterum that is recorded on the company's balance sheet. Investors also form their own opinion of Iterum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Iterum Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iterum Therapeutics' market value can be influenced by many factors that don't directly affect Iterum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iterum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Iterum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iterum Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.